Implantation or Injectable Dosage Form New Animal Drugs; Xylazine

Riepilogo

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Lloyd, Inc. The supplemental NADA provides for use of a 300 milligram per milliliter strength of xylazine hydrochloride solution in elk and wild deer to produce sedation, accompanied by a shorter period of analgesia. A food safety cautionary statement regarding the use of xylazine in elk and wild deer (Cervidae) is also being codified for currently approved products.